We are live on ! Find out more
MRKR icon

Marker Therapeutics
MRKR

36 hedge funds and large institutions have $6.03M invested in Marker Therapeutics in 2025 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 10 increasing their positions, 3 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

233% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 3

95% more capital invested

Capital invested by funds: $3.09M → $6.03M (+$2.94M)

80% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 5

13% more funds holding

Funds holding: 32 → 36 (+4)

2.45% less ownership

Funds ownership: 26.71% → 24.26% (-2.4%)

Holders
36
Holders Change
+4
Holders Change %
+12.5%
% of All Funds
0.44%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
10
Reduced
3
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$191K
2
NA
NewEdge Advisors
Louisiana
+$169K
3
Two Sigma Investments
Two Sigma Investments
New York
+$69.8K
4
Citadel Advisors
Citadel Advisors
Florida
+$66.6K
5
Vanguard Group
Vanguard Group
Pennsylvania
+$52.4K

Top Sellers

Rank Fund Capital Flow
1
TGIA
Torrey Growth & Income Advisors
California
-$46.4K
2
TSS
Two Sigma Securities
New York
-$42.5K
3
VF
Virtu Financial
New York
-$25K
4
Citigroup
Citigroup
New York
-$10.5K
5
I
INVST
Indiana
-$2.27K
Name Holding Trade Value Shares
Change 		Change in
Stake
NMC
1
NEA Management Company
Maryland
$2.42M – – –
BOCH
2
Blue Owl Capital Holdings
New York
$826K – – –
Vanguard Group
3
Vanguard Group
Pennsylvania
$516K +$52.4K +46,293 +15%
ACM
4
Aisling Capital Management
New York
$485K – – –
UBS Group
5
UBS Group
Switzerland
$259K +$191K +168,232 +2,904%
NA
6
NewEdge Advisors
Louisiana
$222K +$169K +149,000 New
Geode Capital Management
7
Geode Capital Management
Massachusetts
$194K +$38.5K +34,028 +35%
Renaissance Technologies
8
Renaissance Technologies
New York
$184K +$19.7K +17,400 +16%
Two Sigma Investments
9
Two Sigma Investments
New York
$146K +$69.8K +61,601 +169%
Osaic Holdings
10
Osaic Holdings
Arizona
$141K +$15.1K +13,340 +16%
LPL Financial
11
LPL Financial
California
$124K +$27.7K +24,500 +42%
Citadel Advisors
12
Citadel Advisors
Florida
$87.7K +$66.6K +58,847 New
XT
13
XTX Topco
Cayman Islands
$86.5K +$41.1K +36,269 +167%
Jane Street
14
Jane Street
New York
$60.4K +$45.9K +40,518 New
BFS
15
Boyer Financial Services
California
$56.7K +$41.7K +36,817 New
I
16
INVST
Indiana
$40.2K -$2.27K -2,000 -7%
Northern Trust
17
Northern Trust
Illinois
$38.8K +$17.2K +15,152 +140%
State Street
18
State Street
Massachusetts
$31.2K – – –
Creative Planning
19
Creative Planning
Kansas
$25.8K – – –
MAA
20
Matrix Asset Advisors
New York
$22.4K – – –
HF
21
HRT Financial
New York
$20K +$15.8K +13,937 New
ATPW
22
Ashton Thomas Private Wealth
Arizona
$14.9K – – –
Fifth Third Bancorp
23
Fifth Third Bancorp
Ohio
$14.9K +$11.3K +10,000 New
IAIM
24
International Assets Investment Management
Florida
$2.98K +$2.27K +2,000 New
Bank of America
25
Bank of America
North Carolina
$1.68K +$3 +3 +0.3%
1
2

MRKR Hedge Fund Activity: Q4 2025 in Review

36 of the 8,232 institutional investors tracked by Wall St. Rank reported a position in Marker Therapeutics (MRKR) for Q4 2025, worth a combined $6.03M — up 95% from $3.09M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new MRKR positions and 5 closed out — a net gain of 4 holders — while 10 added to existing stakes and 3 trimmed.

The largest buyer was UBS Group, adding an estimated $191K. The largest seller was Torrey Growth & Income Advisors, exiting entirely with an estimated $46.4K sold.

  • 36 institutional investors held Marker Therapeutics (MRKR) as of Q4 2025, up from 32 in Q3 2025.
  • Funds reported $6.03M of Marker Therapeutics stock for Q4 2025, up 95% quarter-over-quarter.
  • 9 funds opened new Marker Therapeutics positions in Q4 2025 and 5 closed out, a net change of +4 holders.
  • The largest Marker Therapeutics buyer in Q4 2025 was UBS Group, an estimated $191K added.
  • The largest Marker Therapeutics seller in Q4 2025 was Torrey Growth & Income Advisors, an estimated $46.4K sold.

Based on aggregated 13F filings for Q4 2025.